In adult patients with low-risk thyroid cancer, the probability of persistent disease is low in patients with low or undetectable post-operative TSH stimulated Tg level, and the benefits of RAI administration have been recently questioned [23, 24]. This evidence concerns the gene TG and thyroid gland carcinoma.